Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22749258 | 1.00 | CTSK (0.54) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL9906584 | 0.86 | CTSK (0.50) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL3688912 | 0.86 | CTSK (0.50) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL19993318 | 0.85 | CTSK (0.49) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL7945239 | 0.83 | CTSK (0.38) | CTSKCA1CA2CA7 | |
| SCHEMBL28330954 | 0.79 | CA1 (0.49) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL13365447 | 0.79 | CTSK (0.54) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL8135670 | 0.78 | CTSK (0.38) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL1991719 | 0.78 | CA1 (0.51) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL498987 | 0.78 | CA1 (0.51) | CTSKCA1CA2CA7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177471-A1 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-06-09 | — | — | US | disclosed |
| EP-3980415-A1 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M Innovative Properties Company (US) | 2022-04-13 | — | — | EP | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2020245706-A1 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| EP-1505963-B9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-1505963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20090069322-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2009-03-12 | — | — | US | disclosed |
| WO-2008144925-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2008-12-04 | — | — | WO | disclosed |
| US-7173053-B2 | N-formyl hydroxylamine derivatives as inhibitors of bacterial polypeptide formylase for treating microbial infections | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| EP-1339400-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | VERNALIS OXFORD LTD (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20040106666-A1 | Hydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1339400-A1 | HYDROXAMIC ACID OR N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002041886-A1 | YDROXAMIC ACID OR N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BAKTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2002-05-30 | — | — | WO | disclosed |
| US-5866684-A | Peptidyl inhibitors of viral proteases | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069322-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS | FPR1, FPR3, FPR2 | CTSK 1110/4885CA1 3834/4885CA2 2766/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | CTSK 1909/4885CA1 4815/4885CA2 4743/4885 |
| US-20040106666-A1 | Hydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections | HNMT, ALKBH1, BAK1 | CTSK 1406/4885CA1 2759/4885CA2 1370/4885 |
| US-20220177471-A1 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | IFNG, IFNAR1, IRF3 | CTSK 3049/4885CA1 3799/4885CA2 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.